2223225
Project Grant
Overview
Grant Description
Sbir Phase I: Structure-Guided Design of Anti-Inflammatory Modulators of Protease-Activated Receptor 1 (PAR1) -The broader impact of this Small Business Innovation Research (SBIR) Phase I project is that a deeper structural understanding will be developed of Protease-Activated Receptor 1 (PAR1), an important target for promising new anti-thrombotic and anti-inflammatory drugs. The project will also support the development of new compounds targeting PAR1 with the potential for improved potency and safety profiles.
Such compounds could represent a new drug class for the treatment of inflammation-related diseases, including kidney disease. The proposed project involves the confirmation of the binding site on PAR1 of small molecule ligands called Parmodulins. A detailed characterization of this binding site will support the rapid design, synthesis, and testing of new and improved Parmodulins with superior properties as oral medications.
A combination of computational, structural biology, and synthetic methods will be combined with PAR1 cell assays to confirm the binding site and develop more detailed structure-activity relationships of the Parmodulins. It is also anticipated that novel Parmodulins will be identified in this project with improved safety and stability profiles.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Such compounds could represent a new drug class for the treatment of inflammation-related diseases, including kidney disease. The proposed project involves the confirmation of the binding site on PAR1 of small molecule ligands called Parmodulins. A detailed characterization of this binding site will support the rapid design, synthesis, and testing of new and improved Parmodulins with superior properties as oral medications.
A combination of computational, structural biology, and synthetic methods will be combined with PAR1 cell assays to confirm the binding site and develop more detailed structure-activity relationships of the Parmodulins. It is also anticipated that novel Parmodulins will be identified in this project with improved safety and stability profiles.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding Agency
Place of Performance
Milwaukee,
Wisconsin
53202-2437
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Analysis Notes
Amendment Since initial award the End Date has been extended from 02/29/24 to 08/31/24 and the total obligations have decreased 50% from $549,420 to $274,710.
Function Therapeutics was awarded
Project Grant 2223225
worth $274,710
from in March 2023 with work to be completed primarily in Milwaukee Wisconsin United States.
The grant
has a duration of 1 year 5 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is that a deeper structural understanding will be developed of protease-activated receptor 1 (PAR1), an important target for promising new anti-thrombotic and anti-inflammatory drugs. The project will also support the development of new compounds targeting PAR1 with the potential for improved potency and safety profiles. Such compounds could represent a new drug class for the treatment of inflammation-related diseases, including kidney disease._x000D_ _x000D_ The proposed project involves the confirmation of the binding site on PAR1 of small molecule ligands called parmodulins. A detailed characterization of this binding site will support the rapid design, synthesis, and testing of new and improved parmodulins with superior properties as oral medications. A combination of computational, structural biology, and synthetic methods will be combined with PAR1 cell assays to confirm the binding site and develop more detailed structure-activity relationships of the parmodulins. It is also anticipated that novel parmodulins will be identified in this project with improved safety and stability profiles._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 6/10/24
Period of Performance
3/15/23
Start Date
8/31/24
End Date
Funding Split
$274.7K
Federal Obligation
$0.0
Non-Federal Obligation
$274.7K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2223225
Additional Detail
Award ID FAIN
2223225
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
DMN7SCPC2TR5
Awardee CAGE
982Q2
Performance District
WI-04
Senators
Tammy Baldwin
Ron Johnson
Ron Johnson
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $274,710 | 100% |
Modified: 6/10/24